

NEWS RELEASE



January 21, 2019

Nippon Shinyaku Co., LTD. signs co-promotion agreement with Janssen for apalutamide

Nippon Shinyaku Co., LTD. (Nippon Shinyaku; Headquarters, Kyoto; President, Shigenobu Maekawa) announced a new strategic co-promotion agreement with Janssen Pharmaceutical K.K. (Janssen; Headquarters, Tokyo; President, Chris Hourigan) for apalutamide, a novel oral androgen receptor inhibitor, pending its approval by the Ministry of Health, Labour and Welfare (MHLW) for patients with castration-resistant prostate cancer.

Under the terms of this agreement, promotion of apalutamide to healthcare professionals in Japan will be undertaken by both companies. Janssen will hold the marketing authorization for apalutamide.

Shigenobu Maekawa, president of Nippon Shinyaku said: “We are very pleased to announce the co-promotion agreement of apalutamide with Janssen. Urology is one of the most important disease area for us, we look forward to ensuring broad and rapid access to apalutamide with this strategic agreement.

Apalutamide is an investigational, selective novel oral androgen receptor inhibitor that inhibits the action of testosterone in prostate cancer cells and works by preventing androgen from binding to the androgen receptor (AR). It selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements. It antagonized AR-mediated signaling in AR overexpressing human CRPC cell lines.